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Background: Obesity and its related illnesses are pan-endemic health problems which require intervention.
Laparoscopic Adjustable Gastric Banding (LAGB) is seen as a safe surgical procedure with satisfactory results on
weight reduction and improvement in obesity related illness.
Methods: Data were collected in a repeated-measures longitudinal five year study for 143 morbidly obese patients
who underwent laparoscopic adjustable gastric banding (LAGB). Follow up was continued from 3 to 60 months
post operatively. Patients were assessed for diabetes, hypertension and dyslipidemia.
Results: Repeated measures ANOVAs revealed that both men and women lose weight and reduce their BMIs at a
consistent rate. At 3, 6 and 9 months post-operative there are no differences in percent weight loss between men
and women with mean weight loss at 8.9%, 13.1% and 16.0% respectively of pre-operative weight. At 12, 24 and
60 months post-operatively, however, men significantly increase the percentage of weight loss as well as improve
their BMI compared to women (p < .05). At 24 months post-operative, men and women have BMIs of 36.03 and
32.85, both still in the obese range. By 60 months men have achieved a BMI that is slightly under the obese range
into the overweight range (30.76) while women (BMI = 36.61) were still in the obese range. At 60 months, men
have lost a total of 33.75% of their pre-operative body weight while women have lost a total of 21.50. Diabetes,
hypertension and dyslipidemia were significantly reduced in the sample post-operatively (p < .01).
Conclusion: LAGB is a safe and effective surgical procedure for morbidly obese patients resulting in weight loss,
BMI decrease and reduction in co-morbid illnesses.
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Obesity is recognized as an international health problem
in both developed and developing societies. According
to the World Health Organization (WHO), the preva-
lence of obesity in Bahrain was put at 21.2% and 35.2%
among males and females respectively. The mean body
mass index (BMI) increased dramatically from 24 kg/m2
to 28 kg/m2 and from 25.6 kg/m2 to 29.3 kg/m2 for male* Correspondence: drahmedalansari@gmail.com
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2008 (World Health Organization 2011). In the USA, it
is estimated that over 130 million adults are overweight
or obese. Obesity is now considered to be the most com-
mon cause of death, resulting in 300,000 deaths an-
nually, approximately 14% of all deaths (World Health
Organization 2011). Once an individual becomes obese,
the risk of developing a co-morbid illness such as dia-
betes mellitus (DM), hypertension (HTN), and hyperlip-
idemia increase significantly (Wang et al. 2008). The risk
of type 2 diabetes mellitus (T2DM), for example, has
been shown to increase approximately 40-fold as BMI
increases from <23 kg/m2 to> 35 kg/m2. (Pontiroli 2008).is an Open Access article distributed under the terms of the Creative Commons
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health and quality of life and thus recommended that
studies of health changes associated with weight loss
should be a research priority (Leonardo et al. 1997).
Other Organizations such as the National Institutes of
Health, and surgeons in general, recognize the severity
of obesity and its related co-morbid illnesses (Dixon &
O’Brien 2002). They also acknowledge the impact of
obesity on health, functioning, and well-being (Karmali
et al. 2011). This has resulted in a worldwide increase in
bariatric surgery (Ahroni et al. 2005).
Bariatric surgery is a common treatment for morbid
obesity. Currently the two most common surgical proce-
dures are laparoscopic adjustable gastric banding (LAGB)
and laparoscopic Roux-en Y gastric bypass (LRYGBP).
LRYGBP is the most common bariatric surgery in the
USA whereas in Europe and Australia, LAGB is more
common (Korenkov et al. 2007). Laparoscopic adjustable
gastric banding (LAGB) is seen as a simple and safe sur-
gical procedure in individuals with morbid obesity, with
satisfactory weight loss, improvement in co-morbidities
and significant improvement in quality-of-life (Korenkov
et al. 2007).
Weight loss post bariatric surgery including laparo-
scopic adjustable gastric banding seems to have a major
impact on obesity and its related illnesses (Kinzl et al.
2007). Further research, especially long-term follow-up
studies is required to assess the effectiveness and safety
of LAGB. Moreover, further research of under-studied
populations such as in the Middle East is required for
LAGB. The major purpose of the present study, there-
fore, was to evaluate the impact of laparoscopic adjust-
able gastric banding on weight reduction, BMI decrease
and obesity related illnesses such as diabetes, hyper-
tension, and hyperlipedimia in patients in Bahrain in
a 5 year follow-up.
Methods
Patients
One hundred and forty-three patients (107 women -
74.8% / 36 men - 25.2%; mean age = 29.9, SD=7.16)
underwent LAGB between June 2003 and February 2010.
Patient selection was based on the criteria that has been
identified by the 1991 NIH Consensus Conference Sta-
tement on Gastrointestinal Surgery for Severe Obesity
(Brancatisano et al. 2007).
The mean weight pre-operative for women was 118.74
kg with BMI = 45.75 and for men was 137.51 kg with
BMI = 45.30. Patients were assessed for co-morbidities,
operative time, operative complication, hospital stay, and
follow up at 3, 6, 9, 12, 24 and 60 months. The mean op-
erative time was 70.2 minutes (SD = 23.5). There were no
major complications or patient mortality during the study
period. All patients had undergone various conservativeapproaches (e.g., diet changes) for morbid obesity over a
period of twelve or more months without any effect.Procedures
Surgical technique - All of the LAGB surgeries were per-
formed by a single gastro-intestinal (GI) surgeon (KA) in
one hospital (Bahrain Defense Force Hospital). The pro-
cedure involved insertion of four to five trocars in the
upper abdomen. The band (Swiss adjustable band) was
placed around the fundus of the stomach straight away
below the esophagogastric junction via a retrogastric
tunnel created using the pars flaccid approach. In some
cases, the band was fixed by two or three anterior im-
precating gastro-gastric sutures.
Postoperative first visit - The initial follow up visit was
at one week postoperatively. Reviews continued monthly
for the first year, and then reduced to a visit every two
months in the following years. All adjustments to the
band were performed with 7–8 ml of contrast under fluo-
roscopic imaging.
Co-morbid disease - Patients with the following co-
morbidity (Type 2 Diabetes, Dyslipidemia, and Hyper-
tension) were identified. For each patient suffering from
diabetes, fasting blood sugar and Hba1c was recorded.
Patients with dyslipidemia, cholesterol level and low den-
sity lipoprotein (LDL) were measured. All hypertensive
patients were evaluated according to their blood pressure
measurement and medication dosage pre and postopera-
tively. Co-morbid illness was considered resolved if the
patient no longer required medication after surgery and
specific laboratory values returned to normal. Improve-
ment of co-morbidity was defined by dose reduction in
medication with improvement in specific laboratory
values. Treatment of co-morbid conditions was supervised
by the relevant specialist.
Operative complication - Intra-operative and post ope-
rative complications were recorded. Complications in the
form of intra-operative bleeding, band intolerance, and
wound infection were recorded. No gastric perforation,
necrosis, or band slippages were detected.Data analyses
Data analyses were conducted with SPSS version 19.0.
In addition to descriptive statistics, a two-way repea-
ted measures analysis of variance (2-way rep-ANOVA)
employing sex (2 levels) and time (7 levels) as indepen-
dent variables and BMI as the dependent variable was
conducted. A second 2-way rep-ANOVA employing sex
(2 levels) and time (7 levels) as independent variables
and weight (kg) as the dependent variable was con-
ducted. Changes in co-morbidities were analyzed with
Fisher’s exact test. The level of significance was set at
p < 0.05.
Table 1 BMI, weight and percent weight loss, percent of excess weight loss, compared for men and women
pre-operative and six measurements post-operative
Time BMI Weight (kg) % weight loss % EWL
Sex Mean SD Mean SD n (total 143)
Pre-operative Women 45.75 6.71 118.74 16.90 ———— ———— 107
Men 45.30 5.77 137.51 19.44 ———— ———— 36
3 months post-operative Women 42.01 6.59 108.81 17.39 8.39 17.65 107
Men 40.54 5.07 123.40 18.71 10.28 19.07 36
6 months post-operative Women 40.17 6.50 103.90 17.28 12.49* 26.30* 107
Men 38.39 5.09 116.80 18.60 15.09 27.90 36
9 months post-operative Women 38.88 6.42 100.47 16.81 15.38 32.48 107
Men 36.65 4.82 112.95 20.74 17.94 33.10 36
12 months post-operative Women 37.54* 6.59 97.11 17.13 18.20* 38.47* 107
Men 34.78 4.81 105.86 18.08 22.98 42.70 36
24 months post-operative Women 36.03* 6.84 92.99 17.65 21.69* 45.70* 107
Men 32.85 4.60 100.22 17.32 26.85 50.30 36
60 months post-operative Women 36.61* 8.69 94.58 21.66 21.50* 42.95* 39
Men 30.76 4.85 93.27 19.81 33.75 59.00 13
* p < .05; ** p < .01.
Figure 1 BMI for men and women assessed at months
post-operative.
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Results
There was significant differences in the first 2-way rep-
ANOVA (sex × time) with BMI as the dependent variable
(Time: Wilk’s lambda = 0.156, p < .001; Sex × time: Wilk’s
lambda = 0.922, p < .05) as there was for weight (kg) as
the dependent variable (Time: Wilk’s lambda = 0.030,
p < .001; Sex × time: Wilk’s lambda = 0.833, p < .01).
These results are summarized in Table 1 as are the results
of percentage weight loss over the post-operative period.
Additionally, the change in BMI from pre-operative
to post-operative periods is represented graphically in
Figure 1. A close inspection of Table 1 and Figure 1
reveals that both men and women lose weight and redu-
ce their BMIs at a consistent rate. At 3, 6 and 9 months
post-operative there are no differences in percent weight
loss between men and women with mean weight loss at
8.9%, 13.1% and 16.0% respectively of pre-operative
weight and mean % of (EWL) of 17.65%, 27.9%, and
33.1% (Table 1). At 12, 24 and 60 months post-opera-
tively, however, men significantly (p < .05) increase the
percentage of weight loss as well as improved their BMI
compared to women. This is also evident from Figure 1.
At 24 months post-operative, men and women have
BMIs of 36.03 and 32.85 with EWL 45.7% and 50.3% re-
spectively, both still in the obese range. Although the
sample has had considerable attrition by 60 months, menhave achieved a BMI (30.76) that is marginally outside
the obese range into the overweight range while women
(BMI = 36.61) are still in the obese range. At 60 months,
men have lost a total of 33.75% of their pre-operative body
weight which is equivalent to 59% of (EWL), while women
have lost a total of 21.50% which is representing 42.95%
of (EWL).
Analyses of the co-morbidities (at 24 months) indi-
cated that the majority of diabetics pre-operative (n=18)
were non-diabetic post-operative (n=2 diabetics; Chi
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tients had hyperlipidemia pre-operatively but this number
was reduced to 6 post-operatively (Chi square = 73.6,
Fisher’s exact test < .001). Finally, 14 patients had hy-
pertension pre-operatively and this was reduced to 5
patients post-operatively (Chi square = 96.1, Fisher’s
exact test < .001). There was, therefore, a significant
reduction in all three co-morbidities that were assessed.
Discussion
This is the first study with a five year follow-up of LAGB
in Bahrain. It confirms that LAGB is a safe and effec-
tive surgery with a good result in weight reduction and
changes in co-morbid illnesses. It also confirms that
LAGB can be performed with a minimum of significant
complications, which has been confirmed by other studies
(1991).
Weight loss
Weight reduction is the most commonly reported out-
come measure of bariatric surgery (Frigg et al. 2004).
Bariatric surgery induces a significant loss of fat mass
(FM), and in particular of visceral fat, more than of sub-
cutaneous (Koba et al. 2000). However, weight loss after
LAGB with an average excess weight loss of 50-60% is
less than after gastric bypass or biliopancreatic diversion
(Pontiroli 2008). In the present study, at 60 months,
men have lost a total of 33.75% of their pre-operative
body weight which is 59% of EWL while women have
lost a total of 21.50% which representing 42.96% of
EWL. Although the sample has had considerable attri-
tion by 60 months, men have achieved a BMI (30.76)
that is marginally outside the obese range into the over-
weight range while women (BMI = 36.61) are still in the
obese range. This sex difference requires further investi-
gation as to why women remain in the obese range and
did not continue to lose weight between the period of 24
and 60 months respectively. We speculate that cultural
differences (e.g., higher acceptance of obesity in women
than in men) may play a role these results. Moreover,
pregnancy as well may have contributed to the decreased
weight loss for women which were reported between the
periods of two to five years respectively in this study.
Other studies have reported unexpected pregnancies in
previously infertile women due to weight loss (Weiss
et al. 2001). The effect of weight loss on obesity-related
co-morbidities following LAGB surgery is also a decisive
criterion for success in bariatric surgery in addition to
weight loss and BMI reduction (Dargent 2004; Frigg
et al. 2004).
Diabetes mellitus
LAGB has a dramatic effect on T2DM due to weight loss
induced by gastric banding. This remarkable improvementin diabetes with weight loss, following LAGB surgery is
related to the double effect of improved insulin sensitivity
and pancreatic beta-cell function (Leonardo et al. 1997).
Most gastric band studies have proved that between 66%
and 96% of patients achieve resolution and /or improve-
ment in terms of normalization of laboratory values and
reduction/ or cessation of antidiabetes medication (Kinzl
et al. 2007; Omana et al. 2010). Our results are consistent
with these findings. Out of eighteen patients, 16 (88%)
showed improvement in DM in the period of 2 to 5 years
and two patients showed no improvement.
Hypertension
The high prevalence of hypertension in the morbidly
obese is one of the main risk factors for cardiovascular
disease (Pontiroli et al. 2002). Reports confirm the re-
duction in both systolic and diastolic blood pressure fol-
lowing LAGB (Leonardo et al. 1997). Other studies have
also shown resolution and/or improvement of hyperten-
sion ranging from 47.5% to 86% in obese patients (Kinzl
et al. 2007; Omana et al. 2010). Prior to surgery, many
patients remain hypertensive despite medical therapy.
Several studies have now demonstrated that blood pres-
sure is easier to be controlled post LAGB, and many
patients are able to discontinue antihypertensive medi-
cation (Titi et al. 2007). In the present study the number
of hypertensive patients were reduced from 14 to 5
patients post LAGB surgery representing an improve-
ment in 68.2% of patients with hypertension.
Dyslipidemia
Increased fasting triglyceride and decrease high-density
lipoprotein (HDL) - cholesterol concentration and increa-
sed low-density lipoprotein (LDL) is highly atherogenic
and the most common pattern associated with coronary
disease (Bacci et al. 2002). Weight loss post LAGB is also
associated with improvement in dyslipidemia in the form
of reduction of triglyceride and low-density lipoprotein.
Our result showed that the number of patients with
hyperlipedemia reduced from 19 patients to six patients
post-operatively in concordance with other studies that
have reported improvement in lipid profile ranging from
63.5% to 95% (Kinzl et al. 2007).
Conclusion
LAGB is an effective and safe procedure for weight loss
in morbidly obese patients. After gastric banding, pa-
tients with morbid obesity experience a significant reduc-
tion in major co-morbid illness. The benefit of sustained
significant weight reduction following LAGB surgery on
the serious side-effects of obesity was demonstrated by
its impact on diabetes, hypertension and dyslipidemia.
Therefore, the success of LAGB should be judged by
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co-morbidities.
Notwithstanding the positive results, further research
is required to explore sex differences in the results of
LAGB, as well as other cross-cultural differences that
may exist. Moreover, continued further longitudinal stu-
dies of LAGB will be useful to further evaluate the long
term impact of this bariatric procedure. Meanwhile, the
results of the present study indicate that LAGB is a safe
and effective surgical procedure for morbidly obese pa-
tients resulting in weight loss, BMI decrease and reduc-
tion in co-morbid illnesses.
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